Pegasys - Peginterferon alfa-2a - Roche

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2002年 / 37卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：611 / 612
页数：2
相关论文
共 50 条
  • [21] 40 kDa peginterferon alfa-2a (PEGASYS®) can be administered safely in patients with end-stage renal disease.
    Lamb, MW
    Marks, IM
    Wynohradnyk, L
    Modi, MW
    Preston, RA
    Pappas, SC
    HEPATOLOGY, 2001, 34 (04) : 326A - 326A
  • [22] Predicting response to peginterferon alfa-2a (40 KD) (PEGASYS®) in Asian patients with HBeAg-positive chronic hepatitis B
    Cooksley, Graham
    Chow, Wan Cheng
    Piratvisuth, Teerha
    Lau, George K. K.
    Mccloud, Philip
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A108 - A108
  • [23] Peginterferon alfa-2a versus peginterferon alfa-215 in the treatment of chronic hepatitis C.
    Mauss, S
    Berger, F
    Schmutz, G
    HEPATOLOGY, 2004, 40 (04) : 730A - 730A
  • [24] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 656A - 657A
  • [25] Comparative safety of peginterferon alfa-2a (40 kd) (PEGASYS®) and PEGASYS plus ribavirin (COPEGUS®):: Results of the prospective, randomized, multicenter, open label WINGS™ safety trial
    Rodriguez-Torres, M
    Philip, L
    Shiffman, ML
    Brettholz, E
    Ryan, M
    Hu, S
    Layton, MB
    Badalamenti, S
    HEPATOLOGY, 2004, 40 (04) : 348A - 348A
  • [26] Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Hepatitis C REPLY
    Albrecht, Janice
    McHutchison, John
    Sulkowski, Mark
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (18): : 1809 - 1809
  • [27] Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
    Sierra, Fernando
    JOURNAL OF HEPATOLOGY, 2007, 46 (02) : 349 - 349
  • [28] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [29] Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).
    Ferenci, P
    Shiffman, ML
    Fried, MW
    Sulkowski, MS
    Haeussinger, D
    Zarski, JP
    Goncales, F
    Jensen, DM
    Bonino, F
    Dhumeaux, D
    Blotner, S
    Hoffman, J
    Oliveto, J
    HEPATOLOGY, 2001, 34 (04) : 351A - 351A
  • [30] Asian patients with HBeAg-negative chronic hepatitis B respond well to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment
    Jia, Ji-Dong
    Piratvisuth, Teerha
    Lau, George K. K.
    Luo, Kang-Xian
    Jin, Rui
    Lu, Zhi-Meng
    Marcellin, Patrick
    Popescu, Matei
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A88 - A88
12345